|
| |
Thrombotargets Corporation relocates to Research Triangle Park in North
Carolina
Thrombotargets Corporation announced today that it is relocating its
headquarters in United States to the Research Triangle Park in North Carolina.
The effective date for the relocation is March 1st, 2007.
The new address of Thrombotargets Corporation since that date will be:
2530 Meridian Parkway, Suite 3023
Durham, NC 27713
“The relocation to RTP is an important and necessary step in the growing process
of Thrombotargets” said Dr Pedreño, President/CEO, Thrombotargets Corp.
The decision was taken after analyzing different relocation options and taking
in account that RTP serves as headquarter for more that 145 organizations and
more than 120 research and development-related organizations.
Thrombotargets is willing to start a fruitful collaboration with North Carolina
State Institutions as well as with North Carolina Biotechnology Center and the
three significant Universities located in the vicinity of RTP.
About Thrombotargets Group
Thrombotargets is an emerging biotech group pioneering in the development of a
new generation of High Throughput Screening (HTS) platforms (BioPlatformScreenTM)
useful to discover innovative drugs for the treatment of prevalent and relevant
diseases such as hemorrhagic and thrombotic disorders (acute myocardial
infarction, angina and stroke).
Thrombotargets group is creating a continuously growing and innovative pipeline.
Presently, two of most innovative drug candidates, TT-103MH, a novel
antihemorrhagic human recombinant protein to be use topically, and TT-105, a
novel anticoagulant monoclonal antibody, are undergoing Preclinical trials.
Thrombotargets will start Phase I trial with TT-103 in Q1 2008, and has
presented the Orphan Drug Designation to the FDA for TT-103 MH in December 2006.
TT-111 and TT-112 are two innovative antifibrinolytic compounds, having higher
potency than currently commercialised antifibrinolytic drugs, which are being
developed in collaboration with Asinex, Russia.
Contact
Luis Caveda
Chief Operating Officer
luiscaveda@thrombotargets.com
| |
|
